Brief: HOOKIPA Pharma Doses First Patients With ESEBA-VEC As Adjuvant Therapy In Phase 2 Investigator Lead Trial For Head & Neck Cancer
30/10/2024 11:44
Oct 30 (Reuters) - HOOKIPA Pharma Inc HOOK.O :
* HOOKIPA PHARMA DOSES FIRST PATIENTS WITH ESEBA-VEC AS
ADJUVANT
THERAPY IN PHASE 2 INVESTIGATOR LEAD TRIAL FOR HEAD & NECK
CANCER
* HOOKIPA PHARMA INC - INITIAL SAFETY AND EFFICACY DATA FROM
IIT
EXPECTED IN 2026
Source text: ID:nGNX6mNxzm
Further company coverage: HOOK.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hookipa Pharma
See all newsBrief: Hookipa Pharma Announces Sale Of Oncology Assets To Neotrail Therapeutics
Brief: Hookipa Pharma Announces Intention To Voluntarily Delist And Deregister Its Common Stock
Hookipa Pharma Inc Expected To Post A Loss Of $1.04 A Share: Earnings Preview
Brief: Poolbeg Pharma Says Hookipa Terminated Discussions On Proposed Merger
HOOKIPA Pharma Inc. (“HOOKIPA”) Statement regarding potential combination for Poolbeg Pharma plc (“Poolbeg”)